Related Experiment Video

Updated: Jul 18, 2026

A Method for Mouse Pancreatic Islet Isolation and Intracellular cAMP Determination
12:33

A Method for Mouse Pancreatic Islet Isolation and Intracellular cAMP Determination

Published on: June 25, 2014

Protein kinase C beta inhibition: A novel therapeutic strategy for diabetic microangiopathy

Iskandar Idris1, Richard Donnelly

  • 1John Peace Diabetes Centre, Kings Mill Hospital, Sherwood Hospitals NHS Trust, Sutton in Ashfield, Nottinghamshire, NG17 4JL, UK. iidris@aol.com

Diabetes & Vascular Disease Research
|December 13, 2006
PubMed

Insights

High blood sugar damages blood vessels by activating protein kinase C (PKC). A PKC-beta inhibitor, ruboxistaurin, reduced vision loss in initial studies but did not halt diabetic retinopathy progression.

Area of Science:

  • Biochemistry
  • Vascular Biology
  • Ophthalmology

Background:

  • Hyperglycaemia contributes to vascular damage through cellular signalling pathways.
  • Protein Kinase C (PKC) activation, mediated by diacylglycerol (DAG), plays a key role in these damaging effects.
  • PKC and DAG negatively impact vascular function, leading to increased permeability, leukocyte adhesion, and abnormal cell growth.

Purpose of the Study:

  • To investigate the therapeutic potential of a novel PKC-beta isoform-selective inhibitor, ruboxistaurin.
  • To evaluate the efficacy of ruboxistaurin in mitigating hyperglycaemia-induced vascular damage, specifically in the context of diabetic retinopathy and associated vision loss.

Main Methods:

  • Development of a highly selective and orally active inhibitor targeting the PKC-beta isoform.
  • Clinical studies were conducted to assess the effects of ruboxistaurin on diabetic retinopathy complications.
  • Evaluation of ruboxistaurin's impact on macular oedema, visual loss, and retinopathy progression.

Main Results:

  • Ruboxistaurin demonstrated a reduction in the development of sight-threatening macular oedema.
  • The agent also decreased the occurrence of visual loss associated with diabetic complications.
  • However, ruboxistaurin did not prevent the overall progression of diabetic retinopathy.

Conclusions:

  • Targeting PKC-beta with ruboxistaurin shows promise in managing specific vision-threatening complications of diabetes.
  • Further research is needed to understand the limitations of ruboxistaurin in halting diabetic retinopathy progression.
  • PKC inhibition represents a potential therapeutic strategy for hyperglycaemia-induced vascular damage.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...